Bagsværd, Denmark, 24 April 2019 - At Novo Nordisk's Annual General Meeting on 21 March 2019, it was decided to reduce the company's B share capital from DKK 382,512,800 to DKK 372,512,800 by cancellation of part of the company's portfolio of own B shares equal to a nominal value of DKK 10,000,000 divided into 50,000,000 B shares of DKK 0.20 each.
Today, Novo Nordisk has registered the implementation of the reduction of the share capital with the Danish Business Authority and cancelled B shares at a nominal value of DKK 10,000,000. After the reduction of the share capital, the company's share capital is nominally DKK 480,000,000, which is divided into an A share capital of nominally DKK 107,487,200 and a B share capital of nominally DKK 372,512,800.
The reduction of the share capital will not affect Novo Nordisk's share repurchase programme which will continue as previously announced.
|Anne Margrethe Hauge||+45 4442 email@example.com (mailto:firstname.lastname@example.org)|
|Ken Inchausti (US)||+1 609 786 email@example.com (mailto:firstname.lastname@example.org)|
|Peter Hugreffe Ankersen||+45 3075 email@example.com (mailto:firstname.lastname@example.org)|
|Valdemar Borum Svarrer||+45 3079 email@example.com (mailto:firstname.lastname@example.org)|
|Ann Søndermølle Rendbæk||+45 3075 email@example.com (mailto:firstname.lastname@example.org)|
|Kristoffer Due Berg (US)||+1 609 235 email@example.com (mailto:firstname.lastname@example.org)|
Company announcement no. 24 / 2019
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Novo Nordisk A/S via Globenewswire